Scott A. Golladay

FDA investigator

Appears on 7 documents from 2018 to 2020, mostly at sites in Minnesota. Most often cites responsibilities of quality control unit (21 CFR 211.22).

7
Documents on file
6.0
Observations per 483
2018
First seen
2020
Most recent

What they cite most

From 42 observations

Activity by year

2018: 3, 2019: 2, 2020: 2

Where

Minnesota 5 · Kansas 1 · Wisconsin 1

Is Scott A. Golladay coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

7 documents, newest first
FirmOpen
483 Takeda Pharmaceuticals U.S.A., Inc.Mar 18, 2020 · Brooklyn Park, Minnesota
483 Hospira IncJan 17, 2020 · Mcpherson, Kansas
483 Pharmaceutical Specialties, IncMay 3, 2019 · Rochester, Minnesota
483 Lifecore Biomedical, LLCFeb 26, 2019 · Chaska, Minnesota
483 Upsher Smith Laboratories, Inc.Dec 19, 2018 · Plymouth, Minnesota
483 Upsher Smith Laboratories, IncDec 19, 2018 · Maple Grove, Minnesota
483 SV Labs Prescott CorporationSep 28, 2018 · Prescott, Wisconsin

About this profile

What does Scott A. Golladay inspect?

Scott A. Golladay appears on 7 documents on file covering 7 sites, mostly in Minnesota.

What do they cite most often?

21 CFR 211.22 (responsibilities of quality control unit), followed by 21 CFR 211.68 and 21 CFR 211.100.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Scott A. Golladay is dated Mar 18, 2020.